September 18, 2024 – The number of lives lost around the world due to infections that are resistant to the medications intended to treat them could increase nearly 70% by 2050, a new study just published in the journal The Lancet estimates.

Cumulatively, from 2025 to 2050, the world could see more than 39 million deaths that are directly attributable to antimicrobial resistance or AMR. It is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.

TenNor is developing multiple new antimicrobial drugs with a novel mechanism of action to address the AMR challenges.

TNP-2198 is a synergistic multitargeting drug candidate currently under phase 3 clinical development for the treatment of Helicobacter pylori infections. TNP-2198 is the first new drug in 30 years specifically developed for H. pylori. TNP-2198 can overcome multidrug resistance to antibiotics currently used for the treatment of H. pylori infections.

TNP-2092 is a novel triple acting antibacterial agent with an excellent activity against multidrug resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant S. aureus (QRSA). TNP-2092 possesses an extremely low frequency for the development of resistance. TNP-2092 is currently under phase 3 clinical development for the treatment of prosthetic joint infections.

Link to Lancet article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01076-6/fulltext

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com